Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02676336 · ClinicalTrials.gov registry record · NA
A Randomized Double-blind, Placebo Controlled, Multi-center Study to Evaluate the Safety, Tolerability and Potential Effects of the Dietary Supplement Violet™ Molecular Iodine (I2) on Breast Health in Women With Cyclic Breast Discomfort and Tenderness
A NA study, sponsored by BioPharmX.
- Completed
- Registry status
- NA
- Development phase
- 31
- Enrollment target
NCT02676336 is a NA study that has completed, run by BioPharmX. The registered enrollment target is 31 participants.
The verdict
NCT02676336, a NA study, has completed, sponsored by BioPharmX.
- COMPLETED
- Registry status
- NA
- Development phase
- 31 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo controlled, multi-center study to evaluate the safety, tolerability and potential effects of dietary supplement Violet™ Iodine on breast health in women with cyclic breast discomfort and tenderness to eliminate the evaluation of effectiveness.
Interventions
- OTHER Placebo
- DIETARY_SUPPLEMENT Violet™ Molecular Iodine (I2)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2016-02 |
| Est. Completion | 2018-01-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02676336
The ClinicalTrials.gov registry entry for NCT02676336 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioPharmX, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02676336 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02676336 about?
NCT02676336 is a clinical study titled "A Randomized Double-blind, Placebo Controlled, Multi-center Study to Evaluate the Safety, Tolerability and Potential Effects of the Dietary Supplement Violet™ Molecular Iodine (I2) on Breast Health in Women With Cyclic Breast Discomfort and Tenderness". This is a randomized, double-blind, placebo controlled, multi-center study to evaluate the safety, tolerability and potential effects of dietary supplement Violet™ Iodine on breast health in women with cyclic breast discomfort and tenderness to eliminate the evaluation of effectiveness.
What is the current status of trial NCT02676336?
This trial is currently completed. It is a NA study. The enrollment target is 31 participants. The study started on 2016-02. Estimated completion is 2018-01-31.
What interventions are being tested in trial NCT02676336?
The interventions under investigation include: Placebo (OTHER), Violet™ Molecular Iodine (I2) (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02676336?
This trial is sponsored by BioPharmX, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.